Biotech · Private company
Cantex Pharmaceuticals
Track this companyFree. Adds Cantex Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials62 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- AzeliragonPhase 2 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- AzeliragonPhase 2 · Metastatic Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- Disulfiram/CopperPhase 2 · Recurrent GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- Temozolomide (TMZ)Phase 2 · Recurrent GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed GlioblastomaEARLY_PHASE1 · RECRUITING · started Nov 6, 2025ClinicalTrials.gov NCT06831526 · fetched Nov 12, 2026
- Azeliragon in MGMT Unmethylated GlioblastomaPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 12, 2023ClinicalTrials.gov NCT05986851 · fetched Nov 12, 2026
- Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic CancerPHASE1_PHASE2 · UNKNOWN · started Jun 1, 2023ClinicalTrials.gov NCT05766748 · fetched Nov 12, 2026
- Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple MyelomaPHASE1 · TERMINATED · started May 21, 2021ClinicalTrials.gov NCT04521335 · fetched Nov 12, 2026
- Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or GemcitabinePHASE2 · TERMINATED · started Oct 17, 2019ClinicalTrials.gov NCT03714555 · fetched Nov 12, 2026
- Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent GlioblastomaPHASE2 · COMPLETED · started Mar 9, 2017ClinicalTrials.gov NCT03034135 · fetched Nov 12, 2026